SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- AI adoption surges, but providers worry about deskilling (Healthcare Dive)
- The gastroenterologist pay gap (Becker’s GI & Endoscopy)
- 8 No Surprises Act shake-ups physicians need to know (Becker’s Healthcare)
- ChristianaCare researchers identify genetic drivers of aggressive CRC (Becker’s GI & Endoscopy)
- A Collaborative Approach for Advanced IBD Therapy Prior Authorization Denials (GI & Endoscopy News)
- Personalized Nutrition: The Future of Gastroenterology (Grand View Research)
- Mindray Leads the Evolution of Gastroenterology Imaging with the Newly Expanded Hepatus-Series Ultrasound Systems (PR Newswire)
- How NYU Langone is helping modernize a decades-old GI surgery tool (Becker’s GI & Endoscopy)
